Dr Boreham’s Crucible: Regeneus has pain sorted; now for long-term gain

Flush with fresh funding, the stem cell play’s overhauled management is supremely confident of striking a partnering deal in Japan pertaining to its lead osteoarthritis treatment Progenza.

This confident assertion – accompanied by a $5.54 million capital raising – lifts a burden of guilt for your columnist, who late last year put the mozz on the company by describing its board – barely changed since the company’s listing in 2013 – as remarkably stable.

Read the full article via Stockhead here.